# Post-marketing Surveillance for the Clinical Safety and Effectiveness of Eribulin Mesylate in Patients With Inoperable or Recurrent Breast Cancer (Study HAL01S)

> **NCT01463891** · — · COMPLETED · sponsor: **Eisai Co., Ltd.** · enrollment: 963 (actual)

## Conditions studied

- Inoperable or Recurrent Breast Cancer

## Interventions

- **DRUG:** Eribulin Mesylate

## Key facts

- **NCT ID:** NCT01463891
- **Lead sponsor:** Eisai Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2011-07-19
- **Primary completion:** 2012-12-26
- **Final completion:** 2013-11-27
- **Target enrollment:** 963 (ACTUAL)
- **Last updated:** 2023-07-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01463891

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01463891, "Post-marketing Surveillance for the Clinical Safety and Effectiveness of Eribulin Mesylate in Patients With Inoperable or Recurrent Breast Cancer (Study HAL01S)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01463891. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*